Trial Profile
A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs AUTO-3 (Primary) ; Cyclophosphamide; Fludarabine; Pembrolizumab
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms AMELIA
- Sponsors Autolus
- 23 Feb 2023 Results (n=52; data cut Feb 28, 2022) assessing safety and efficacy of CD19/22 dual-targeting CAR-T (AUTO3) plus pembrolizumab in relapsed/refractory large B cell lymphoma as inpatient or outpatient therapy, published in the Blood.
- 01 Oct 2021 Results (n=15; data cut-off 1 June 2020) assessing pre-clinical experiments with AUTO3 together with the safety and efficacy results of this phase 1 clinical trial, published in the Nature Medicine.
- 13 Jul 2020 Status changed from active, no longer recruiting to completed.